274 related articles for article (PubMed ID: 23519018)
1. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.
Ma C; Cheung AF; Chodon T; Koya RC; Wu Z; Ng C; Avramis E; Cochran AJ; Witte ON; Baltimore D; Chmielowski B; Economou JS; Comin-Anduix B; Ribas A; Heath JR
Cancer Discov; 2013 Apr; 3(4):418-29. PubMed ID: 23519018
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.
Chodon T; Comin-Anduix B; Chmielowski B; Koya RC; Wu Z; Auerbach M; Ng C; Avramis E; Seja E; Villanueva A; McCannel TA; Ishiyama A; Czernin J; Radu CG; Wang X; Gjertson DW; Cochran AJ; Cornetta K; Wong DJ; Kaplan-Lefko P; Hamid O; Samlowski W; Cohen PA; Daniels GA; Mukherji B; Yang L; Zack JA; Kohn DB; Heath JR; Glaspy JA; Witte ON; Baltimore D; Economou JS; Ribas A
Clin Cancer Res; 2014 May; 20(9):2457-65. PubMed ID: 24634374
[TBL] [Abstract][Full Text] [Related]
3. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
Kalbasi A; Shrimali RK; Chinnasamy D; Rosenberg SA
J Immunother; 2010 Sep; 33(7):672-83. PubMed ID: 20664359
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.
Nowicki TS; Escuin-Ordinas H; Avramis E; Chmielowski B; Chodon T; Berent-Maoz B; Wang X; Kaplan-Lefko P; Yang L; Baltimore D; Economou JS; Ribas A; Comin-Anduix B
J Immunother; 2018 Jun; 41(5):248-259. PubMed ID: 29470191
[TBL] [Abstract][Full Text] [Related]
5. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
6. Hit parade for adoptive cell transfer therapy: the best T cells for superior clinical responses.
Speiser DE
Cancer Discov; 2013 Apr; 3(4):379-81. PubMed ID: 23580281
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
8. Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells.
Ding R; Liu S; Wang S; Chen H; Wang F; Xu Q; Zhu L; Dong X; Gu Y; Zhang X; Chao CC; Gao Q
Theranostics; 2021; 11(10):4957-4974. PubMed ID: 33754038
[No Abstract] [Full Text] [Related]
9. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.
Phan GQ; Rosenberg SA
Cancer Control; 2013 Oct; 20(4):289-97. PubMed ID: 24077405
[TBL] [Abstract][Full Text] [Related]
10. Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.
Höfflin S; Prommersberger S; Uslu U; Schuler G; Schmidt CW; Lennerz V; Dörrie J; Schaft N
Cancer Biol Ther; 2015; 16(9):1323-31. PubMed ID: 26178065
[TBL] [Abstract][Full Text] [Related]
11. A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor.
Landoni E; Smith CC; Fucá G; Chen Y; Sun C; Vincent BG; Metelitsa LS; Dotti G; Savoldo B
Cancer Immunol Res; 2020 Jan; 8(1):57-69. PubMed ID: 31719055
[TBL] [Abstract][Full Text] [Related]
12. Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Laurent J; Speiser DE; Appay V; Touvrey C; Vicari M; Papaioannou A; Canellini G; Rimoldi D; Rufer N; Romero P; Leyvraz S; Voelter V
J Immunother; 2010 Sep; 33(7):723-34. PubMed ID: 20664354
[TBL] [Abstract][Full Text] [Related]
13. TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.
Govers C; Sebestyén Z; Roszik J; van Brakel M; Berrevoets C; Szöőr Á; Panoutsopoulou K; Broertjes M; Van T; Vereb G; Szöllősi J; Debets R
J Immunol; 2014 Nov; 193(10):5315-26. PubMed ID: 25320284
[TBL] [Abstract][Full Text] [Related]
14. TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features.
Simon S; Wu Z; Cruard J; Vignard V; Fortun A; Khammari A; Dreno B; Lang F; Rulli SJ; Labarriere N
Front Immunol; 2018; 9():1962. PubMed ID: 30214446
[TBL] [Abstract][Full Text] [Related]
15. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
16. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
[TBL] [Abstract][Full Text] [Related]
17. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
18. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
19. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
Seiter S; Monsurro V; Nielsen MB; Wang E; Provenzano M; Wunderlich JR; Rosenberg SA; Marincola FM
J Immunother; 2002; 25(3):252-63. PubMed ID: 12000867
[TBL] [Abstract][Full Text] [Related]
20. Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.
Jazirehi AR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
